Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : BMS scores China's first IO approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/18/2018 | 10:27am CEST

China's State Drug Administration approved Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY), marking the country's first approval of an immuno-oncology agent, according to the pharma. The anti-PD-1 mAb is indicated to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior platinum-based chemotherapy in adult patients without EGFR or ALK mutations.

The application, which had received Priority Review, included data from the Phase III CheckMate -078 trial in which 90% of enrolled patients were Chinese.

BMS spokesperson Priyanka Shah said the company expects Opdivo to be available next half. BMS is preparing to submit pricing material to the relevant authorities.

In April, the China State Council said all cancer drugs would be exempt from import tariffs and would be incorporated into China's National Reimbursement Drug List. Manufacturers may have to agree to steep discounts to get their drugs onto the Chinese market as a result.

Shah said the pharma was "working with the government and other stakeholders on possible public health programs" to provide access to the drug but did not go into detail.

At least three other NDAs for anti-PD-1 mAbs are under Priority Review in China: sintilimab (IBI308) from Innovent Biologics Inc. (Suzhou, China); camrelizumab (SHR-1210) from Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:3600276); and according to media outlets, Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK).

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.76% 62.03 Delayed Quote.10.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
10:27aBRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/17BRISTOL MYERS SQUIBB : Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dex..
BU
06/15BRISTOL MYERS SQUIBB : China National Drug Administration Approves Country&rsquo..
BU
06/15BRISTOL MYERS SQUIBB : to Present New Research Findings on the Treatment of Pati..
AQ
06/14BRISTOL MYERS SQUIBB : Trademark Application for "OBREFCO" Filed by Bristol-Myer..
AQ
06/14BRISTOL MYERS SQUIBB : Patent Issued for Radioligands for Imaging the LPA-1 Rece..
AQ
06/14STUDIES FROM BRISTOL-MYERS SQUIBB YI : ...
AQ
06/14REPORTS OUTLINE LUNG CANCER STUDY RE : Quantitative analysis of specific potenti..
AQ
06/14BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Lifts Partial Clinical ..
AQ
06/14BRISTOL MYERS SQUIBB : Opdivo Plus Chemotherapy Showed Improved Progression-Free..
AQ
More news
News from SeekingAlpha
06/17WEEK IN REVIEW : Mevion Medical Of Boston Closes $150 Million Financing From Chi.. 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
06/14Bristol-Myers Squibb declares $0.40 dividend 
06/13FHLC : A Bet On American Demographics 
06/12Bristol Meyers Top NASH Contenders 
Financials ($)
Sales 2018 21 740 M
EBIT 2018 5 499 M
Net income 2018 4 486 M
Finance 2018 428 M
Yield 2018 2,97%
P/E ratio 2018 19,36
P/E ratio 2019 16,48
EV / Sales 2018 4,10x
EV / Sales 2019 3,78x
Capitalization 89 573 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 57,3 $
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-10.57%89 573
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880